arrow
T

Tobias Menne

Newcastle upon Tyne Hospitals NHS Foundation Trust
H指数:30
被引数:5,186

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T-cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized-controlled trial

诱导治疗后给予一周期Nelarabine在T细胞前体急性淋巴细胞白血病患者中耐受性良好,但并未改善成人患者的预后:来自UKALL14随机对照试验的结果数据

2026-10-010
OAAI
Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK

英国大型B细胞淋巴瘤患者接受二线阿西替尼西洛鲁塞注射液治疗的结局

2026-02-190
OAAI
Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial

联合使用MEK抑制剂塞鲁美替尼和地塞米松可在RAS通路突变的复发/难治性急性淋巴细胞白血病患者中实现应答:一项平行队列、剂量探索和扩展的I/II期试验结果

2026-02-010
OAAI
Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

CAR T细胞制备失败的风险因素及大B细胞淋巴瘤患者结局:英国国家CAR T小组报告

2025-03-042
OA
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

成人b细胞急性淋巴细胞白血病的Obecabtagene自体白血病

2024-12-120
PRE
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab

一线Ph阴性b细胞前体急性淋巴细胞白血病的治疗和blinatumomab的新兴作用

2024-11-190
OAAI
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial
2024-11-110
OAAI
A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

英国对Brexucabtagene Autoleucel治疗复发或难治性成人急性淋巴细胞白血病1年治疗后的意向性治疗分析

BLOOD
IF23.1
2024-11-050
PRE
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy
2024-05-212
OAAI
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes
2024-04-040
OAAI
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study
2023-08-3113
OAAI
Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing

通过抗体检测预测免疫功能低下人群的新型冠状病毒肺炎感染风险

LANCET
IF88.5
2023-07-015
OAAI
Bendamustine plus rituximab for the treatment of Waldenstrom Macroglobulinemia: Patient outcomes and impact of bendamustine dosing
2023-03-206
OAAI
Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
2023-01-243
OA
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
2022-05-0921
OAAI
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study

在b细胞恶性肿瘤中接种两剂和三剂疫苗后对SARS-CoV-2变体的免疫反应: 英国普罗塞奥研究

2022-03-2457
OAAI